Literature DB >> 2311019

Surgical management of giant pituitary adenomas.

G Mohr1, J Hardy, R Comtois, H Beauregard.   

Abstract

During the past 25 years, 77 giant pituitary adenomas have been treated surgically, including suprasellar extensions of type C in 66 cases and of type D in 11 cases. Non-secreting adenomas were present in 53 and secreting adenomas in 24 cases. All patients except 3 presented with significant visual field defects; including bitemporal hemianopia, superior quadranopia or unilateral temporal hemianopia, contralateral blindness in 73% of the cases, and one case with sudden bilateral blindness due to acute pituitary apoplexy. A single transsphenoidal procedure was carried out in 74% of the patients while 11 patients (7%) required re-operations for recurrent or residual tumor. Only 3 patients required a subsequent transcranial procedure. Complications included 1 CSF-leak, 1 empty-sella syndrome and 4 fatal post-operative hematomas. We prefer the transsphenoidal route even in very large or giant pituitary adenomas, since it allows rapid and adequate decompression of the optic nerves and chiasm, avoids major pituitary insufficiency in 60% of the cases and is associated with low morbidity-mortality rates.

Entities:  

Mesh:

Year:  1990        PMID: 2311019     DOI: 10.1017/s0317167100030055

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  23 in total

1.  Intercavernous venous communications in the human skull base.

Authors:  M G Aquini; A C Marrone; F L Schneider
Journal:  Skull Base Surg       Date:  1994

2.  Microsurgical management of giant pituitary tumors.

Authors:  W A King; G E Rodts; D P Becker; D Q Mc Bride
Journal:  Skull Base Surg       Date:  1996

3.  The current role of transcranial surgery in the management of pituitary adenomas.

Authors:  Ravindran Pratheesh; Simon Rajaratnam; Krishna Prabhu; Sunithi E Mani; Geeta Chacko; Ari G Chacko
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

4.  Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery.

Authors:  Christoph P Hofstetter; Michael J Nanaszko; Lynn L Mubita; John Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

5.  Cavernous Sinus Involvement by Pituitary Adenomas: Clinical Implications and Outcomes of Endoscopic Endonasal Resection.

Authors:  Abdulrazag Ajlan; Achal S Achrol; Abdulrahman Albakr; Abdullah H Feroze; Erick M Westbroek; Peter Hwang; Griffith R Harsh
Journal:  J Neurol Surg B Skull Base       Date:  2017-01-23

6.  Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients.

Authors:  Sumit Sinha; Avijit Sarkari; A K Mahapatra; B S Sharma
Journal:  Childs Nerv Syst       Date:  2014-04-29       Impact factor: 1.475

Review 7.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

8.  Intraoperative magnetic resonance imaging-guided transsphenoidal surgery for giant pituitary adenomas.

Authors:  Fabian Baumann; Christoph Schmid; René-Ludwig Bernays
Journal:  Neurosurg Rev       Date:  2009-10-13       Impact factor: 3.042

9.  Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes.

Authors:  Muhammad Omar Chohan; Ariana M Levin; Ranjodh Singh; Zhiping Zhou; Carlos L Green; Jacob J Kazam; Apostolos J Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

10.  Pre- and postoperative magnetic resonance imaging appearance of the normal residual pituitary gland following macroadenoma resection: Clinical implications.

Authors:  Salvatore Di Maio; Arundhati Biswas; Jean Lorrain Vézina; Jules Hardy; Gérard Mohr
Journal:  Surg Neurol Int       Date:  2012-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.